Aviatrix Announces 10,000th “Aviatrix Certified Engineer” (ACE) Milestone and Introduces New Multi-Cloud Network Operations Certification
16.2.2021 17:00:00 EET | Business Wire | Press release
Aviatrix, the cloud network platform, today announced it has reached yet another significant milestone with its Aviatrix Certified Engineers (ACE) Program, while also launching a new multi-cloud network operations curriculum that builds on the basic cloud networking knowledge required to achieve ACE Multi-Cloud Networking Associate certification. The designation ACE Multi-Cloud Network Operations validates a cloud networking professional’s ability to successfully operate and manage multi-cloud networking and security services that support their organization’s needs. This course also introduces CI/CD and Infrastructure-as-a-Code (IaC) concepts, as more innovative solutions for operating cloud networking and security. Automation tools such as Terraform and the Aviatrix multi-cloud Terraform provider help operations an DevOps teams work closely together to deploy a repeatable and auditable infrastructure, leveraging a single CI/CCD pipeline.
With over 10,000 ACEs representing more than 2,500 companies, in over 110 countries worldwide, the Aviatrix ACE Program is the leading and most recognized multi-cloud networking technical certification. Specifically, this training program has helped cloud networking professionals and their companies close the skills gap, learn basic cloud service provider (CSP) constructs and how to add value by learning best practices for multi-cloud network architectures.
“Cloud networking is important but is also very complex. The Aviatrix ACE Program allows me to better understand the designs and limitations of all major cloud service providers (AWS, Azure, GCP, OCI, etc.,). This valuable education also helps architects and engineers design and build enterprise-class cloud networking solutions that meet enterprise-class security, performance, and compliance requirements. I strongly recommend this program to anyone interested in learning more about Hybrid or Multi-Cloud networking,” exclaimed Walter Lee, Sr. Software Engineer, at a leading global financial services company.
The ACE Program helps prepare an organization’s technical staff to lead and accelerate their transformation to cloud. The program is the first multi-cloud networking and security certification available to cloud practitioners, DevOps, networking staff, and security professionals. The ACE certification is designed for individuals who understand basic networking concepts and prepares engineers and operations staff with knowledge on (1) native cloud networking constructs in AWS, Azure, Google Cloud, and Oracle Cloud Infrastructure and (2) multi-cloud design patterns and concepts and (3) proficiency to plan and provision multi-cloud network use cases and architecture using the Aviatrix cloud network platform.
“The industry demand for the ACE Program over the past 12 months continues to exceed our expectations,” said Nauman Mustafa, Vice President Solutions Engineering, at Aviatrix. “With ACE, we provide the required training cloud networking professionals need to fully understand public-cloud networking constructs, service provider capabilities, different multi-cloud architectural design patterns, and how to apply this knowledge to their specific environment. Furthermore, our newly launched multi-cloud network operations course will enable the ACEs to successfully run, operate and efficiently manage their business-critical workloads in the cloud. They will also gain greater visibility, observability, and monitoring capabilities that go well beyond the basic operations and troubleshooting tools they get from their CSPs.”
Join the ACE Community Today!
To learn more about the ACE program, including the schedule for self-paced and instructor-led courses, course curriculum and other details, visit https://aviatrix.com/ace/. Or email us at ace@aviatrix.com to request more information.
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005239/en/
Contact information
PR Contact:
Aviatrix
Dmitry Lipkin
dlipkin@aviatrix.com
408-888-2792
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom